AORT vs NNOX vs NVCR vs SYK

For growth investors, Nano-X Imaging Ltd.

(NNOX) is the stronger pick with 13. 9% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Stryker Corporation (SYK) offers the better valuation at 34. 0x trailing P/E (19. 1x forward), making it the more compelling value choice. Analysts rate Artivion, Inc. (AORT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Stryker Corporation (SYK) is the cheapest at 34.

0x versus Artivion, Inc. at 121. 0x. On forward P/E, Stryker Corporation is actually cheaper at 19. 1x.

Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +17.

5%, compared to -93. 4% for Nano-X Imaging Ltd. (NNOX). Over 10 years, the gap is even starker: SYK returned +179. 2% versus NNOX's -96. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.

52β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 310% more volatile than SYK relative to the S&P 500. On balance sheet safety, Nano-X Imaging Ltd. (NNOX) carries a lower debt/equity ratio of 4% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nano-X Imaging Ltd.

(NNOX) is pulling ahead at 13. 9% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: Artivion, Inc. grew EPS 165. 6% year-over-year, compared to 8. 2% for Stryker Corporation. Over a 3-year CAGR, NNOX leads at 105. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Stryker Corporation (SYK) is the more profitable company, earning 12.

9% net margin versus -474. 3% for Nano-X Imaging Ltd. — meaning it keeps 12. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus -502. 9% for NNOX. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Stryker Corporation (SYK) trades at 19.

1x forward P/E versus 75. 3x for Artivion, Inc. — 56. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NNOX: 940. 5% to $18. 00.

In this comparison, SYK (1.

2% yield) pays a dividend. AORT, NNOX, NVCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52), 1. 2% yield, +179. 2% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +179. 2%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

SYK pays a dividend while AORT, NNOX, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.